SLNCF — Silence Therapeutics plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1479615 ·
United Kingdom
Last close
$1.50
Market Cap
$212.56M
52W High
$2.63
52W Low
$1.06
ADV30
590
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 422,000 | 411,000 | -15,737,000 | -14,957,000 | 115,123,000 | 5,657,000 | 65,721,000 |
| Dec 2025 | 34,000 | 22,000 | -12,461,000 | -11,770,000 | 131,442,000 | 11,277,000 | 69,138,000 |
| Sep 2025 | 159,000 | 95,000 | -26,244,000 | -20,958,000 | 146,790,000 | 82,031,000 | 72,727,000 |
| Jun 2025 | 224,000 | 139,000 | -22,639,000 | -27,354,000 | 165,233,000 | 41,739,000 | 71,078,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,271,000
Investing CF
$-47,992,000
Financing CF
$15,000
CapEx
$-110,768
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-562,572,000
Inventory
—
Receivables
$24,614,000
ST Investments
$73,837,000
EBIT TTM
$-89,753,000
Pretax Income TTM
$-88,601,000
Interest Exp TTM
$11,511,234
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$839,000
EBITDA
$-71,083,000
Free Cash Flow
$-45,655,752
Enterprise Value
$142,610,768
Total Cash
$70,078,000
Total Debt
$136,000
Shares Out
141,703,840
Trailing EPS
$-0.54
Book Value
$0.35
ROE
-92.6%
ROA
-29.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 559,000 | -89,753,000 | -88,612,000 | 131,442,000 | 69,138,000 | — | -62,271,000 |
| Dec 2024 | 43,258,000 | -63,319,000 | -45,309,000 | 202,635,000 | 68,612,000 | — | -67,640,000 |
| Dec 2023 | 31,643,000 | -64,383,000 | -54,228,000 | 119,448,000 | 97,455,000 | — | -49,462,000 |
| Dec 2022 | 21,655,000 | -61,040,000 | -50,334,000 | 130,096,453 | 103,384,928 | — | -57,044,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MSLE | Satellos Bioscience Inc. | $208.10M | $9.99 | — |
| ACIU | AC Immune SA | $222.88M | $2.19 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $222.96M | $3.85 | — |
| KROS | Keros Therapeutics, Inc. | $199.30M | $10.07 | — |
| GLSI | Greenwich LifeSciences, Inc. | $198.16M | $13.50 | — |
News headlines (Yahoo Finance, 1h cache)
Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential
2026-06-30 13:06 · Yahoo
How Silence Therapeutics (SLN) Is Building the Divesiran Case Around Fewer Blood Draws in Polycythemia Vera
2026-06-17 15:16 · Yahoo
This Silence Therapeutics Insider Increased Their Holding In The Last Year
2026-05-12 10:07 · Yahoo
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
2026-04-16 12:50 · Yahoo
We Think Silence Therapeutics (NASDAQ:SLN) Needs To Drive Business Growth Carefully
2026-04-01 10:16 · Yahoo
European Equities Traded in the US as American Depositary Receipts Higher Monday
2026-03-16 15:22 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
2026-03-10 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
2026-03-09 15:30 · Yahoo
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
2026-03-05 14:55 · Yahoo
European Equities Traded in the US as American Depositary Receipts Tumble in Monday Trading
2026-03-02 16:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.